Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer

US11142588B2 · kind B2 · utility

Assignee

• ADALTA LIMITED · AU

Inventors

• Michael Foley · New York, US
• Andrew James Pow · Burlingame, US
• Katherine Griffiths · Melbourne, AU
• Samantha Cobb · Melbourne, AU
• Katerina Viduka · Melbourne, AU

Key dates

• Filing date: Dec 18, 2019
• Grant date: Oct 12, 2021
• Expiry date: Dec 18, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/323
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to polypeptides (also referred to herein as CXCR4 binding molecules or polypeptides) that are directed against the G-coupled protein receptor CXCR4, also known as Fusin or CD184. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptide; to compositions, and in particular to pharmaceutical compositions that comprise such polypeptides and to uses of such polypeptides for therapeutic or diagnostic purposes.